로그인 회원가입
icon_bulk_order대량 주문 Acrobiosystems for English
0
장바구니가 비어 있습니다
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: > Cell > Fc gamma RIIB / CD32b > SCCHO-ATP060L

CHO/Human CD32b Stable Cell Line (Low Expression) Development Service

  1. Genetically modified cell lines best reflect MOA (Mechanism of Action)
  2. Higher activity and larger assay window for robust and reproducible cell-based bioassay
  3. Comprehensive application data to support assay development and validation
  4. Full tracible record, stringent quality control and validated cell passage stability
  5. Parental cell line legally obtained from internationally recognized cell resource bank and commercially licensed
  6. Global commercial license assistance whenever regulatory filing is required
  • Description
    The CHO/Human CD32b Stable Cell Line was engineered to express full length human CD32b receptor (Gene ID: 2213), with different levels of CD32b expression (High, Medium, Low), which can be used to test agonist antibody whether in a CD32b-dependent manner to strengthen the agonistic activity. When co-cultured with Human 4-1BB HEK293 Reporter Cell and anti-4-1BB agonist antibody, the anti-4-1BB antibody can be crosslinked, thereby strengthening 4-1BB pathway-activated luminescence.
  • Application

    • Useful for cell-based CD32b binding assay

    • Useful for CD32b-mediated crosslinking

     Fc gamma RIIB / CD32b Assay Principles

  • Growth Properties
    Adherent
  • Selection Marker
    Hygromycin (20 μg/mL)
  • Culture Medium
    F-12K+ 10% FBS
  • Freeze Medium
    Serum-free cell cryopreservation medium
  • Quantity
    1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium
  • Storage
    Frozen in liquid nitrogen.
  • Mycoplasma Testing
    Negative
  • Sterility Testing
    Negative
  • Instructions for Use
    See data sheet for detailed culturing and assay protocol.
Receptor Assay
 Fc gamma RIIB / CD32b FACS

Expression analysis of human CD32b on CHO/Human CD32b Stable Cell Line by FACS.
Cell surface staining using PE/Cy7-labeled anti-human CD32b antibody was performed on CHO/Human CD32b Stable Cell Line with different expression levels: CHO/Human CD32b Stable Cell Line (Low Expression); CHO/Human CD32b Stable Cell Line (Medium Expression); CHO/Human CD32b Stable Cell Line (High Expression).

Please contact us if you are interested in related cell pool service.

  • Background
    Receptors for the Fc region of IgG (Fc γ R) are members of the Ig superfamily that function in the activation or inhibition of immune responses. Three classes of human Fc γ Rs: RI (CD64), RII (CD32), and RIII (CD16), which generate multiple isoforms, are recognized. There are three genes for human Fcγ RII /CD32 (A, B, and C) and one for mouse Fcγ RII B (CD32B). CD32 is a low affinity receptor for IgG. Low affinity immunoglobulin gamma Fc region receptor II-b (FCGR2B) is also known as CD32b, FCG2, IGFR2. CD32B is expressed on B cells and myeloid dendritic cells. Ligation of CD32B on B cells downregulates antibody production and may, in some circumstances, promote apoptosis. Co-ligation of CD32B on dendritic cells inhibits maturation and blocks cell activation. CD32B may also be a target for monoclonal antibody therapy for malignancies.
  • Limited Use&License Disclosure
    1. This cell line is provided for research use only and a MTA (Material Transfer Agreement) is required for such purpose. It is neither intended for any animal or human therapeutic use nor for any direct human in vivo use. You are restricted to share, modify, transfer, distribute, sell, sublicense, or otherwise make the cell line available for use to other researchers, laboratories, research institutions, hospitals, universities, or service organizations.
    2. ACROBIOSYSTEMS MAKES NO WARRANTIES OR REPRESENTATIONS OF ANY KIND, EITHER EXPRESSED OR IMPLIED, WITH RESPECT TO THE SUITABILITY OF THE CELL LINE FOR ANY PARTICULAR USE.
    3. ACROBIOSYSTEMS ACCEPTS NO LIABILITY IN CONNECTION WITH THE HANDLING OR USE OF THE CELL LINE.
    4. Modifications of the cell line, transfer to a third party, or commercial use of the cell line may require a separate license and additional fees. Please contact order@acrobiosystems.com for further details.
  • Clinical and Translational Updates

코멘트 (0)


재고상품 출발날짜: 영업일 기준 4일

가격(KRW) : 5,250,000

보급 및 전시



약물 개발 현황

  • Number of Launched Drugs:0 Details
  • Number of Drugs in Clinical Trials:5 Details
  • Latest Research Phase:Phase 3 Clinical

Datasheet & Documentation

신제품

문의와 컨텐츠

This web search service is supported by Google Inc.

totop